- BioCryst Pharmaceuticals ( NASDAQ: BCRX ) on Wednesday named its chief medical officer Bill Sheridan as its new chief development officer.
- Senior vice president of global medical affairs Ryan Arnold, who joined BioCryst in March 2022, has been appointed as the company’s new chief medical officer.
- Sheridan joined BioCryst in July 2008 from Amgen, where he led the company’s medical affairs functions in the U.S. and Europe.
- Earlier: BioCryst wins FDA’s Orphan Drug status for bone disorder therapy
For further details see:
BioCryst Pharmaceuticals promotes Sheridan to development chief